These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 14760427)

  • 1. Cytokines as therapeutic targets for the gastrointestinal manifestations of scleroderma.
    Raoul JM; Verma M; Tan E; Peterson TC
    Can J Gastroenterol; 2004 Jan; 18(1):22-4. PubMed ID: 14760427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pathogenesis of systemic scleroderma: immunological aspects].
    Mouthon L; García De La Peña-Lefebvre P; Chanseaud Y; Tamby MC; Boissier MC; Guillevin L
    Ann Med Interne (Paris); 2002 May; 153(3):167-78. PubMed ID: 12218899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis.
    Denton CP; Abraham DJ
    Curr Opin Rheumatol; 2001 Nov; 13(6):505-11. PubMed ID: 11698729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of TGF-beta signaling in the pathogenesis of fibrosis in scleroderma.
    Ihn H
    Arch Immunol Ther Exp (Warsz); 2002; 50(5):325-31. PubMed ID: 12455866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe fibrosis and increased expression of fibrogenic cytokines in the gastric wall of systemic sclerosis patients.
    Manetti M; Neumann E; Milia AF; Tarner IH; Bechi P; Matucci-Cerinic M; Ibba-Manneschi L; Müller-Ladner U
    Arthritis Rheum; 2007 Oct; 56(10):3442-7. PubMed ID: 17907149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Future treatments in systemic sclerosis.
    Asano Y
    J Dermatol; 2010 Jan; 37(1):54-70. PubMed ID: 20175840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What are the new milestones in the pathogenesis of systemic sclerosis?
    Hunzelmann N; Brinckmann J
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i52-56. PubMed ID: 19995745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the TGFbeta, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma.
    Leask A
    Cell Signal; 2008 Aug; 20(8):1409-14. PubMed ID: 18296024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine regulation of pulmonary fibrosis in scleroderma.
    Atamas SP; White B
    Cytokine Growth Factor Rev; 2003 Dec; 14(6):537-50. PubMed ID: 14563355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis.
    Igarashi A; Nashiro K; Kikuchi K; Sato S; Ihn H; Grotendorst GR; Takehara K
    J Invest Dermatol; 1995 Aug; 105(2):280-4. PubMed ID: 7636314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autocrine TGF-beta signaling in the pathogenesis of systemic sclerosis.
    Ihn H
    J Dermatol Sci; 2008 Feb; 49(2):103-13. PubMed ID: 17628443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis genes in systemic sclerosis.
    Shi-wen X; Pennington D; Holmes A; Leask A; Bradham D; Beauchamp JR; Fonseca C; du Bois RM; Martin GR; Black CM; Abraham DJ
    Exp Cell Res; 2000 Aug; 259(1):213-24. PubMed ID: 10942593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into the molecular mechanism of chronic fibrosis: the role of connective tissue growth factor in scleroderma.
    Leask A; Denton CP; Abraham DJ
    J Invest Dermatol; 2004 Jan; 122(1):1-6. PubMed ID: 14962082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Connective tissue growth factor causes persistent proalpha2(I) collagen gene expression induced by transforming growth factor-beta in a mouse fibrosis model.
    Chujo S; Shirasaki F; Kawara S; Inagaki Y; Kinbara T; Inaoki M; Takigawa M; Takehara K
    J Cell Physiol; 2005 May; 203(2):447-56. PubMed ID: 15605379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pathophysiologic aspects of systemic sclerosis].
    Gran JT; Molberg Ø; Midtvedt Ø
    Tidsskr Nor Laegeforen; 2005 Oct; 125(19):2622-3. PubMed ID: 16215604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypothesis: pathogenesis of systemic sclerosis.
    Takehara K
    J Rheumatol; 2003 Apr; 30(4):755-9. PubMed ID: 12672195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic sclerosis. A clinical overview.
    Generini S; Fiori G; Moggi Pignone A; Matucci Cerinic M; Cagnoni M
    Adv Exp Med Biol; 1999; 455():73-83. PubMed ID: 10599326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologics in systemic sclerosis.
    Xuan J; Shen L; Zhang C; Ambrus JL
    Curr Pharm Biotechnol; 2014; 15(6):549-57. PubMed ID: 25213364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway.
    Sambo P; Baroni SS; Luchetti M; Paroncini P; Dusi S; Orlandini G; Gabrielli A
    Arthritis Rheum; 2001 Nov; 44(11):2653-64. PubMed ID: 11710721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis.
    Sato S; Nagaoka T; Hasegawa M; Tamatani T; Nakanishi T; Takigawa M; Takehara K
    J Rheumatol; 2000 Jan; 27(1):149-54. PubMed ID: 10648031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.